These include not only considering CTC subtypes but also combining CTC-related parameters with clinicopathological factors (e.g., tumor severity, lymph node metastasis, vascular invasion) and tumor markers (e.g., CEA, CA72-4, CA 19-9) to establish a multimarker model for predicting CRC recurrence. Here, CEACAM5 is linked to neoplasm.